Request availability and a quotation for your required quantity and destination.
| Product | Tirzepatide 2.5 mg - Mounjaro KwikPen |
|---|---|
| Categories | Weight Loss |
| Availability | Confirmed on enquiry |
Product listing is not a recommendation to use this medicine. Prescription and destination requirements apply where relevant.
Active ingredient: Tirzepatide
Strength: 2.5 mg
Dosage form: Prefilled injection pen
Medicine class: GIP and GLP-1 receptor agonist
Dose-stage context: starting dose
Prescription status: Prescription medicine
Mounjaro 2.5 mg contains tirzepatide, a once-weekly medicine that acts on glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Depending on the country and approved indication, tirzepatide is used for type 2 diabetes and/or chronic weight management in eligible adults. This is the usual starting strength and is used to begin dose escalation. Treatment should be prescribed and monitored by a qualified healthcare professional.
Where approved for weight management, tirzepatide is used alongside a reduced-calorie diet and increased physical activity in eligible adults with obesity, or overweight with qualifying weight-related conditions. Eligibility differs by country and health system, so patients should follow local prescribing criteria rather than self-selecting treatment based on BMI alone.
Tirzepatide activates both GIP and GLP-1 receptors. These incretin pathways influence appetite, energy intake and glucose regulation. For weight management, treatment works best as part of a broader plan that includes nutrition, activity and ongoing clinical review.
Tirzepatide is generally administered once weekly by subcutaneous injection. Current UK guidance starts treatment at 2.5 mg once weekly and increases the dose gradually in 2.5 mg steps, normally after at least 4 weeks at the current dose. Do not start at a higher strength, accelerate escalation or switch doses without the prescriber’s direction.
A healthcare professional should review medical history, other diabetes medicines, pregnancy plans and relevant gastrointestinal, pancreatic, gallbladder or kidney concerns before treatment. Gastrointestinal adverse effects can contribute to dehydration. Hypoglycaemia risk can increase when tirzepatide is combined with insulin or medicines such as sulfonylureas, and those treatments may require clinical review.
Seek prompt medical advice for severe or persistent abdominal pain, serious allergic-reaction symptoms, persistent vomiting or other significant unexpected symptoms. Tirzepatide should not be combined with or substituted for another incretin medicine without professional guidance.
Nausea, diarrhoea, vomiting, constipation and other gastrointestinal symptoms can occur, particularly during dose escalation. Tolerability varies. Persistent or severe symptoms should be assessed by a healthcare professional.
Cureiva lists the Mounjaro KwikPen strength pathway for product research: Mounjaro 2.5 mg, Mounjaro 5 mg, Mounjaro 7.5 mg, Mounjaro 10 mg, Mounjaro 12.5 mg, Mounjaro 15 mg. These internal links help patients understand the available presentations; they are not instructions to change dose.
For treatment research, see semaglutide 0.25 mg – Wegovy, liraglutide – Saxenda and orlistat 120 mg – Orligal. These medicines differ in mechanism, approved indications, contraindications and dosing and should not be considered interchangeable.
See NICE guidance on tirzepatide for managing overweight and obesity and the current official product information applicable in the patient’s country. External clinical references are provided for independent medical context and do not replace a prescription or individual assessment.
Mounjaro contains tirzepatide. Approved uses vary by country and can include type 2 diabetes and weight management in eligible patients. A clinician should confirm the appropriate indication.
2.5 mg is the usual starting dose.
Tirzepatide is generally administered once weekly. Patients should follow the instructions for their prescribed presentation.
Response varies and should be assessed over time. Early treatment includes gradual dose escalation, and clinicians review weight response, tolerability and whether continued treatment is appropriate.
Mounjaro contains tirzepatide and acts on GIP and GLP-1 receptors. Wegovy contains semaglutide and acts on GLP-1 receptors. Indications and dosing differ by jurisdiction, and the medicines are not automatically interchangeable.
Dose changes should follow the prescriber’s escalation plan. Do not move to a higher strength simply because it is available.
Yes. Cureiva Healthcare handles international product enquiries subject to availability, prescription requirements, temperature-controlled transport considerations where applicable and destination-country import rules.
Related patient guide: Mounjaro nausea, vomiting and dehydration warning signs. Educational information only; follow advice from your treating clinician.
Cureiva Healthcare provides product information and handles international enquiries subject to applicable prescription and import requirements. This content is educational and does not replace official product information, diagnosis or advice from a qualified healthcare professional.
Last content review: October 2026